



Biotech Daily

Tuesday February 7, 2017

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH DOWN: LIVING CELL UP 15%, BENITEC DOWN 6%**
- * **APPLICATIONS OPEN FOR 3 VICTORIA \$800k RESEARCH FELLOWSHIPS**
- * **MEDICAL DEVELOPMENTS PENTHROX ROLL-OUT, MORE INDICATIONS**
- * **CELLMID HAIR GROWTH PATENT**
- * **MACH7 TO RELEASE 6m ASX ESCROW SHARES**
- * **ZELDA ISSUES 8m ADVISORY BOARD OPTIONS**
- * **ACTINOGEN ISSUES 5m EMPLOYEE OPTIONS**
- * **MGC TAKES 80% OF PANAX, 20% OPTION**
- * **OVENTUS APPOINTS STEVEN WICK NORTH AMERICA BDM**

MARKET REPORT

The Australian stock market climbed 0.11 percent on Tuesday February 7, 2017 with the ASX200 up 6.3 points to 5,621.9 points.

Seven of the Biotech Daily Top 40 stocks were up, 20 fell, eight traded unchanged and five were untraded. All three Big Caps were up.

Living Cell was the best, up 1.5 cents or 15.0 percent to 11.5 cents with 903,349 shares traded.

Neuren climbed 7.4 percent; Prima and Psivida rose more than two percent; Cochlear, Osprey, Polynovo and Resmed were up more than one percent; with Airxpanders and CSL up by less than one percent.

Benitec led the falls, down one cent or 6.1 percent to 15.5 cents with 939,726 shares traded.

Opthea and Viralytics lost five percent or more; Factor Therapeutics fell 4.55 percent; Actinogen was down 3.6 percent; Anteo, Compumedics, Ellex, Mesoblast and Uscom shed more than two percent; Nanosonics, Orthocell, Pharmaxis, Prana, Sirtex and Starpharma were down more than one percent; with Clinuvel, Impedimed, Medical Developments and Pro Medicus down by less than one percent.

VICTORIA GOVERNMENT

The Victoria Government says applications have opened for three four-year Health and Medical Research Fellowships, each worth \$800,000.

The Minister for Health Jill Hennessy said the program would support health and medical researchers by supporting a university, health service or medical research institute to employ researchers working in bioinformatics, genomics and health services research. A Victoria Government media release said that the fellowship program was part of the \$20 million 'Healthier Lives, Stronger Economy: Victoria's Health and Medical Research Strategy 2016-2020'.

The media release said that strategy detailed six priority areas: to develop the workforce of the future; integrate research education and health; develop advanced convergence science; stimulate more industry engagement; attract more clinical trials; and optimise big data and informatics.

The Government said that for more information on the Victorian Health and Medical Research Fellowships go to: www.biomedvic.org.au/fellowships/.

MEDICAL DEVELOPMENTS INTERNATIONAL

Medical Developments says its UK and Ireland distributor Galen has rolled out its inhaled methoxyflurane analgesic Pentrox the 34 hospitals including St George's.

Medical Developments said that London's St George's Hospital had approved the use of Pentrox in its accident and emergency department one of the UK's largest.

Medical Developments chief executive officer John Sharman said the company expected "of additional hospitals and ambulance trusts to approve Pentrox in the coming months".

The company said that a 240-patient paediatric trial planned for 10 sites UK and Ireland sites was expected to enrol its first patient by July 2017, adding to the paediatric data base from its 300-patient pivotal phase III 'Stop' study (BD: Jan 21, 2013).

Medical Developments said the data collected would be used to expand the indication for Pentrox into the paediatric population in Europe and other markets as well as support its application for US approval.

The company said that with its Europe distributor Mundipharma, it was developing a clinical trial program to extend the Pentrox indications to surgical procedures, with enrolment beginning in 2018 and a trial for a second indication in Europe in 2019.

"Our focus is on extending the use of Pentrox in markets around the world and the data generated from these trials will play an important role in the future growth of Pentrox globally," Mr Sharman said.

Medical Developments fell two cents or 0.4 percent to \$5.00.

CELLMID

Cellmid says the European Patent Office allowed a patent entitled 'Method of Treatment or Prevention of Hair Loss or for Enhancement of Hair Growth'.

Cellmid said that the European "midkine alopecia" patent would provide intellectual property protection until February 2031 and adds to other allowances in the US, Japan, Australia and UK for the same patent family.

The company said that the patents were opportunities for subsidiary Advangen which was developing and commercializing hair loss technologies.

Cellmid said that results presented in the patent were "particularly relevant to hair loss caused by chemotherapy agents".

Cellmid was unchanged at 3.2 cents.

[MACH7 TECHNOLOGIES](#)

Mach7 says that 5,874,817 shares issued in relation to the 3D Medical acquisition will be released from ASX escrow on February 18, 2017 (BD: Oct 26, 2015; Apr 8, 2016).

Following the release, there will be 70,012,228 shares available for trading with a further 44,193,300 shares held in ASX escrow until April 8, 2017, 339,850 shares in ASX escrow until June 1, 2017 and 57,690 shares in ASX escrow until July 1, 2017, making the total number of shares in the company 118,205,528 shares.

Mach7 said that 4,289,245 unlisted options exercisable at 50 cents each, which were issued in connection with the acquisition, lapsed yesterday February 6, 2017.

Mach7 fell half a cent or 1.5 percent to 33 cents.

[ZELDA THERAPEUTICS](#)

Zelda says it has issued 8,000,000 employee share option plan options to members of its medical advisory board, or their nominees.

Zelda said the board comprised Prof Manuel Guzmán, Prof Dr Cristina Sánchez, Dr Joe Goldstrich and Dr Noah Federman and each would receive 2,000,000 options.

The company said that 2,000,000 options exercisable at four cents each, vesting immediately and would expire on February 6, 2020, with 6,000,000 options exercisable at four cents each would vest on February 6, 2019 and expire on February 6, 2020.

Zelda fell 0.2 cents or 6.25 percent to three cents.

[ACTINOGEN MEDICAL](#)

Actinogen says it has issued 4,950,000 employee option plan options, exercisable at 10 cents each, expiring on February 5, 2021.

Actinogen said that the majority would vest subject to the achievement of pre-defined targets in patient recruitment for its Xanadu trial of Xanemem for Alzheimer's disease over a two-year period and the balance would vesting two years from the date of issue.

The company said it proposed to issue up to 3,000,000 options to corporate advisors exercisable at 10 cents each and expiring 24 months from the date of issue, but the timing of the option issue was yet to be determined.

Actinogen fell 0.2 cents or 3.6 percent to 5.4 cents

[MGC \(MEDICAL GRADE CANNABIS\) PHARMACEUTICALS](#)

MGC it has settled a binding heads of agreement to acquire up to 100 percent of the Czech-based medical cannabis company Panax Pharma SRO.

MGC said that the two companies would collaborate to develop a medical cannabis genetics and breeding research program.

The company said that the Institute of Experimental Botany of the Academy of Sciences would begin research operations at its Prague growing facilities following the grant of a medical cannabis breeding license.

MGC said that it held 80 percent of Panax, with the right to increase this to 100 percent for EUR600,000 (\$A837,451) of MGC shares.

MGC was up 0.2 cents or five percent to 4.2 cents with 2.8 million shares traded.

OVENTUS MEDICAL

Oventus says it has appointed Steven Wick as North America business development manager.

Oventus said that Mr Wick was an experienced sales and marketing professional with 26 years in the healthcare industry including dental and sleep disorders.

The company said that previously Mr Wick lead Incisal Edge Sleep for dentists wanting to add obstructive sleep apnoea to their practices.

Oventus said that Mr Wick wrote the patient resource book 'Kicking the Bear out of the Bedroom', "which subsequently became an Amazon best seller".

The company said that Mr Wick worked for four years in dental sales and education for Somnomed.

Oventus was up one cent or 1.3 percent to 79 cents.